Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review

The Lancet Gastroenterology and Hepatology

Volumn 2, Issue 4, 2017, Pages 288-297

  Harris, Rebecca ^a   Harman, David J ^a   Card, Timothy R ^a,b   Aithal, Guruprasad P ^a   Guha, Indra Neil ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL LIVER DISEASE; ALGORITHM; ELASTOGRAPHY; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER FUNCTION TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING TEST; SYSTEMATIC REVIEW; ASYMPTOMATIC DISEASE; CHRONIC DISEASE; EARLY DIAGNOSIS; MASS SCREENING; PROCEDURES; RISK ASSESSMENT;

ASYMPTOMATIC DISEASES; CHRONIC DISEASE; EARLY DIAGNOSIS; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; LIVER FUNCTION TESTS; MASS SCREENING; PREVALENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 85017251072     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(16)30205-9     Document Type: Review

References (50)

1. 1 GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388 (2016), 1459–1544.
2. 2 Mokdad, AA, Lopez, AD, Shahraz, S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med, 12, 2014, 145.
3. 3 Leon, DA, McCambridge, J, Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. Lancet 367 (2006), 52–56.
4. 4 Bhala, N, Aithal, G, Ferguson, J, How to tackle rising rates of liver disease in the UK. BMJ, 346, 2013, f807.
5. 5 Blachier, M, Leleu, H, Peck-Radosavljevic, M, Valla, DC, Roudot-Thoraval, F, The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 58 (2013), 593–608.
6. 6 Williams, R, Ashton, K, Aspinall, R, et al. Implementation of the Lancet Standing Commission on Liver Disease in the UK. Lancet 386 (2015), 2098–2111.
7. 7 Ginès, P, Graupera, I, Lammert, F, et al. Screening for liver fibrosis in the general population: a call for action. Lancet Gastroenterol Hepatol 1 (2016), 256–260.
8. 8 Ratib, S, Fleming, KM, Crooks, CJ, Aithal, GP, West, J, 1 and 5 year survival estimates for people with cirrhosis of the liver in England, 1998–2009: a large population study. J Hepatol 60 (2014), 282–289.
9. 9 McLernon, DJ, Donnan, PT, Ryder, S, et al. Health outcomes following liver function testing in primary care: a retrospective cohort study. Fam Pract 26 (2009), 251–259.
10. 10 Mofrad, P, Contos, MJ, Haque, M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37 (2003), 1286–1292.
11. 11 Skelly, MM, James, PD, Ryder, SD, Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 35 (2001), 195–199.
12. 12 Fracanzani, AL, Valenti, L, Bugianesi, E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48 (2008), 792–798.
13. 13 European Association for Study of Liver Disease, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 63 (2015), 237–264.
14. 14 Friedrich-Rust, M, Ong, MF, Martens, S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 134 (2008), 960–974.
15. 15 Angulo, P, Hui, JM, Marchesini, G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45 (2007), 846–854.
16. 16 Harrison, SA, Oliver, D, Arnold, HL, Gogia, S, Neuschwander-Tetri, BA, Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 57 (2008), 1441–1447.
17. 17 Higgins, JPT, Green, S, Cochrane handbook for systematic reviews of interventions. Version 5.1.0, 2011, The Cochrane Collaboration http://handbook.cochrane.org/ (accessed Dec 14, 2014).
18. 18 Liberati, A, Altman, DG, Tetzlaff, J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62 (2009), e1–34.
19. 19 Baba, M, Furuya, K, Bandou, H, Kasai, K, Sadaoka, K, Discrimination of individuals in a general population at high-risk for alcoholic and non-alcoholic fatty liver disease based on liver stiffness: a cross section study. BMC Gastroenterol, 11, 2011, 70.
20. 20 Wong, VW, Chu, WC, Wong, GL, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 61 (2012), 409–415.
21. 21 You, SC, Kim, KJ, Kim, SU, et al. Factors associated with significant liver fibrosis assessed using transient elastography in general population. World J Gastroenterol 21 (2015), 1158–1166.
22. 22 Lemoine, M, Shimakawa, Y, Njie, R, et al. Food intake increases liver stiffness measurements and hampers reliable values in patients with chronic hepatitis B and healthy controls: the PROLIFICA experience in The Gambia. Aliment Pharmacol Ther 39 (2014), 188–196.
23. 23 Malik R, Cheshire L, Jalan R. Development and evaluation of a liver health programme for asymptomatic subjects at risk of liver disease. 60th annual meeting of the American Association for the Study of Liver Disease; Boston; 2009. 789A–90A.
24. 24 Fabrellas, N, Alemany, M, Urquizu, M, et al. Using transient elastography to detect chronic liver diseases in a primary care nurse consultancy. Nurs Res 62 (2013), 450–454.
25. 25 Zelber-Sagi, S, Ratziu, V, Zvibel, I, et al. The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury: a study in the general population. Eur J Gastroenterol Hepatol 24 (2012), 262–269.
26. 26 Poynard, T, Lebray, P, Ingiliz, P, et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol, 10, 2010, 40.
27. 27 Roulot, D, Costes, JL, Buyck, JF, et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 60 (2011), 977–984.
28. 28 Veysey, M, Siow, W, Niblett, S, King, K, Yates, Z, Lucock, M, Hepatic fibrosis in an elderly population. J Gastroenterol Hepatol, 29, 2014, 87.
29. 29 Armstrong, MJ, Houlihan, DD, Bentham, L, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 56 (2012), 234–240.
30. 30 Kim, D, Kim, WR, Kim, HJ, Therneau, TM, Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57 (2013), 1357–1365.
31. 31 Grattagliano, I, Napoli, L, Marulli, CF, et al. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The “VARES” Italian multicenter study. Ann Hepatol 12 (2013), 70–77.
32. 32 Williamson, RM, Price, JF, Hayes, PC, et al. Prevalence and markers of advanced liver disease in type 2 diabetes. QJM 105 (2012), 425–432.
33. 33 Morling, JR, Fallowfield, JA, Guha, IN, et al. Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study. J Hepatol 60 (2014), 384–391.
34. 34 Das, K, Das, K, Mukherjee, PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 51 (2010), 1593–1602.
35. 35 Sheron, N, Moore, M, O'Brien, W, Harris, S, Roderick, P, Feasibility of detection and intervention for alcohol-related liver disease in the community: the Alcohol and Liver Disease Detection study (ALDDeS). Br J Gen Pract 63 (2013), e698–e705.
36. 36 Moessner, BK, Jorgensen, TR, Skamling, M, et al. Outreach screening of drug users for cirrhosis with transient elastography. Addiction 106 (2011), 970–976.
37. 37 Harman, DJ, Ryder, SD, James, MW, et al. Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography. BMJ Open, 5, 2015, e007516.
38. 38 Nguyen-Khac, E, Chatelain, D, Tramier, B, et al. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Aliment Pharmacol Ther 28 (2008), 1188–1198.
39. 39 Nahon, P, Kettaneh, A, Tengher-Barna, I, et al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol 49 (2008), 1062–1068.
40. 40 Prati, D, Taioli, E, Zanella, A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137 (2002), 1–10.
41. 41 Fleming, KM, Aithal, GP, Solaymani-Dodaran, M, Card, TR, West, J, Incidence and prevalence of cirrhosis in the United Kingdom, 1992–2001: a general population-based study. J Hepatol 49 (2008), 732–738.
42. 42 Jepsen, P, Vilstrup, H, Sørensen, HT, Alcoholic cirrhosis in Denmark—population-based incidence, prevalence, and hospitalization rates between 1988 and 2005: a descriptive cohort study. BMC Gastroenterol, 8, 2008, 3.
43. 43 Roulot, D, Czernichow, S, Le Clesiau, H, Costes, JL, Vergnaud, AC, Beaugrand, M, Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 48 (2008), 606–613.
44. 44 Conti, F, Vukotic, R, Foschi, FG, et al. Transient elastography in healthy subjects and factors influencing liver stiffness in non-alcoholic fatty liver disease: an Italian community-based population study. Dig Liver Dis 48 (2016), 1357–1363.
45. 45 Imbert-Bismut, F, Messous, D, Thibault, V, et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 42 (2004), 323–333.
46. 46 Imbert-Bismut, F, Ratziu, V, Pieroni, L, Charlotte, F, Benhamou, Y, Poynard, T, for the MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357 (2001), 1069–1075.
47. 47 Ekstedt, M, Hagstrom, H, Nasr, P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
48. 48 Ratziu, V, Charlotte, F, Heurtier, A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128 (2005), 1898–1906.
49. 49 Boursier, J, Vergniol, J, Guillet, A, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by Fibroscan in non-alcoholic fatty liver disease. J Hepatol 65 (2016), 570–578.
50. 50 European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64 (2016), 1388–1402.